Endothelial barrier protection by FTY720 under hyperglycemic condition: Involvement of focal adhesion kinase, small GTPases, and adherens junction proteins

Kei Sarai, Kenichi Shikata, Yasushi Shikata, Kazuyoshi Omori, Naomi Watanabe, Motofumi Sasaki, Shingo Nishishita, Jun Wada, Noriko Goda, Noriyuki Kataoka, Hirofumi Makino

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Recently, sphingosine 1-phosphate (S1P) has been highlighted as an endothelial barrier-stabilizing mediator. FTY720 is a S1P analog originally developed as a novel immunosuppressant. The phosphorylated form of FTY720 binds to S1P receptors to exert S1P-like biological effects, suggesting endothelial barrier promotion by FTY720. To elucidate whether FTY720 induces signaling events related to endothelial barrier enhancement under hyperglycemic conditions, human microvascular endothelial cells (HMVECs) preincubated with hyperglycemic (30 mM) medium were treated with 100 nM FTY720 for 3 h. Immunofluorescent microscopy and coprecipitation study revealed FTY720-induced focal adhesion kinase (FAK)-associated adherens junction (AJ) assembly at cell-cell contacts coincident with formation of a prominent cortical actin ring. FTY720 also induced transmonolayer electrical resistance (TER) augmentation in HMVEC monolayers in both normoglycemic and hyperglycemic conditions, implying endothelial barrier enhancement. Similar to S1P, site-specific FAK tyrosine phosphorylation analysis revealed FTY720-induced FAK [Y576] phosphorylation without phosphorylation of FAK [Y397/Y 925]. Furthermore, FTY720 conditioned the phosphorylation profile of FAK [Y397/Y576/Y925] in hyperglycemic medium to the same pattern observed in normoglycemic medium. FTY720 challenge resulted in small GTPase Rac activation under hyperglycemic conditions, whereas increased Rho activity in hyperglycemic medium was restored to the basal level. Rac protein depletion by small interfering RNA (siRNA) technique completely abolished FTY720-induced FAK [Y576] phosphorylation. These findings strongly suggest the barrier protective effect of FTY720 on HMVEC monolayers in hyperglycemic medium via S1P signaling, further implying the possibility of FTY720 as a therapeutic agent of diabetic vascular disorder.

Original languageEnglish
JournalAmerican Journal of Physiology - Cell Physiology
Volume297
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

Adherens Junctions
Focal Adhesion Protein-Tyrosine Kinases
Monomeric GTP-Binding Proteins
Proteins
Phosphorylation
Endothelial Cells
Fingolimod Hydrochloride
rac GTP-Binding Proteins
Lysosphingolipid Receptors
Immunosuppressive Agents
Electric Impedance
Small Interfering RNA
Blood Vessels
Tyrosine
Actins
Microscopy

Keywords

  • Cytoskeleton
  • Diabetes mellitus
  • Endothelial barrier function
  • Human microvascular endothelial cell
  • Transmonolayer electrical resistance

ASJC Scopus subject areas

  • Cell Biology
  • Physiology

Cite this

Endothelial barrier protection by FTY720 under hyperglycemic condition : Involvement of focal adhesion kinase, small GTPases, and adherens junction proteins. / Sarai, Kei; Shikata, Kenichi; Shikata, Yasushi; Omori, Kazuyoshi; Watanabe, Naomi; Sasaki, Motofumi; Nishishita, Shingo; Wada, Jun; Goda, Noriko; Kataoka, Noriyuki; Makino, Hirofumi.

In: American Journal of Physiology - Cell Physiology, Vol. 297, No. 4, 2009.

Research output: Contribution to journalArticle

Sarai, Kei ; Shikata, Kenichi ; Shikata, Yasushi ; Omori, Kazuyoshi ; Watanabe, Naomi ; Sasaki, Motofumi ; Nishishita, Shingo ; Wada, Jun ; Goda, Noriko ; Kataoka, Noriyuki ; Makino, Hirofumi. / Endothelial barrier protection by FTY720 under hyperglycemic condition : Involvement of focal adhesion kinase, small GTPases, and adherens junction proteins. In: American Journal of Physiology - Cell Physiology. 2009 ; Vol. 297, No. 4.
@article{b41712ed7b9f4bc89844f3b04dbd7c84,
title = "Endothelial barrier protection by FTY720 under hyperglycemic condition: Involvement of focal adhesion kinase, small GTPases, and adherens junction proteins",
abstract = "Recently, sphingosine 1-phosphate (S1P) has been highlighted as an endothelial barrier-stabilizing mediator. FTY720 is a S1P analog originally developed as a novel immunosuppressant. The phosphorylated form of FTY720 binds to S1P receptors to exert S1P-like biological effects, suggesting endothelial barrier promotion by FTY720. To elucidate whether FTY720 induces signaling events related to endothelial barrier enhancement under hyperglycemic conditions, human microvascular endothelial cells (HMVECs) preincubated with hyperglycemic (30 mM) medium were treated with 100 nM FTY720 for 3 h. Immunofluorescent microscopy and coprecipitation study revealed FTY720-induced focal adhesion kinase (FAK)-associated adherens junction (AJ) assembly at cell-cell contacts coincident with formation of a prominent cortical actin ring. FTY720 also induced transmonolayer electrical resistance (TER) augmentation in HMVEC monolayers in both normoglycemic and hyperglycemic conditions, implying endothelial barrier enhancement. Similar to S1P, site-specific FAK tyrosine phosphorylation analysis revealed FTY720-induced FAK [Y576] phosphorylation without phosphorylation of FAK [Y397/Y 925]. Furthermore, FTY720 conditioned the phosphorylation profile of FAK [Y397/Y576/Y925] in hyperglycemic medium to the same pattern observed in normoglycemic medium. FTY720 challenge resulted in small GTPase Rac activation under hyperglycemic conditions, whereas increased Rho activity in hyperglycemic medium was restored to the basal level. Rac protein depletion by small interfering RNA (siRNA) technique completely abolished FTY720-induced FAK [Y576] phosphorylation. These findings strongly suggest the barrier protective effect of FTY720 on HMVEC monolayers in hyperglycemic medium via S1P signaling, further implying the possibility of FTY720 as a therapeutic agent of diabetic vascular disorder.",
keywords = "Cytoskeleton, Diabetes mellitus, Endothelial barrier function, Human microvascular endothelial cell, Transmonolayer electrical resistance",
author = "Kei Sarai and Kenichi Shikata and Yasushi Shikata and Kazuyoshi Omori and Naomi Watanabe and Motofumi Sasaki and Shingo Nishishita and Jun Wada and Noriko Goda and Noriyuki Kataoka and Hirofumi Makino",
year = "2009",
doi = "10.1152/ajpcell.00606.2008",
language = "English",
volume = "297",
journal = "American Journal of Physiology",
issn = "0002-9513",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Endothelial barrier protection by FTY720 under hyperglycemic condition

T2 - Involvement of focal adhesion kinase, small GTPases, and adherens junction proteins

AU - Sarai, Kei

AU - Shikata, Kenichi

AU - Shikata, Yasushi

AU - Omori, Kazuyoshi

AU - Watanabe, Naomi

AU - Sasaki, Motofumi

AU - Nishishita, Shingo

AU - Wada, Jun

AU - Goda, Noriko

AU - Kataoka, Noriyuki

AU - Makino, Hirofumi

PY - 2009

Y1 - 2009

N2 - Recently, sphingosine 1-phosphate (S1P) has been highlighted as an endothelial barrier-stabilizing mediator. FTY720 is a S1P analog originally developed as a novel immunosuppressant. The phosphorylated form of FTY720 binds to S1P receptors to exert S1P-like biological effects, suggesting endothelial barrier promotion by FTY720. To elucidate whether FTY720 induces signaling events related to endothelial barrier enhancement under hyperglycemic conditions, human microvascular endothelial cells (HMVECs) preincubated with hyperglycemic (30 mM) medium were treated with 100 nM FTY720 for 3 h. Immunofluorescent microscopy and coprecipitation study revealed FTY720-induced focal adhesion kinase (FAK)-associated adherens junction (AJ) assembly at cell-cell contacts coincident with formation of a prominent cortical actin ring. FTY720 also induced transmonolayer electrical resistance (TER) augmentation in HMVEC monolayers in both normoglycemic and hyperglycemic conditions, implying endothelial barrier enhancement. Similar to S1P, site-specific FAK tyrosine phosphorylation analysis revealed FTY720-induced FAK [Y576] phosphorylation without phosphorylation of FAK [Y397/Y 925]. Furthermore, FTY720 conditioned the phosphorylation profile of FAK [Y397/Y576/Y925] in hyperglycemic medium to the same pattern observed in normoglycemic medium. FTY720 challenge resulted in small GTPase Rac activation under hyperglycemic conditions, whereas increased Rho activity in hyperglycemic medium was restored to the basal level. Rac protein depletion by small interfering RNA (siRNA) technique completely abolished FTY720-induced FAK [Y576] phosphorylation. These findings strongly suggest the barrier protective effect of FTY720 on HMVEC monolayers in hyperglycemic medium via S1P signaling, further implying the possibility of FTY720 as a therapeutic agent of diabetic vascular disorder.

AB - Recently, sphingosine 1-phosphate (S1P) has been highlighted as an endothelial barrier-stabilizing mediator. FTY720 is a S1P analog originally developed as a novel immunosuppressant. The phosphorylated form of FTY720 binds to S1P receptors to exert S1P-like biological effects, suggesting endothelial barrier promotion by FTY720. To elucidate whether FTY720 induces signaling events related to endothelial barrier enhancement under hyperglycemic conditions, human microvascular endothelial cells (HMVECs) preincubated with hyperglycemic (30 mM) medium were treated with 100 nM FTY720 for 3 h. Immunofluorescent microscopy and coprecipitation study revealed FTY720-induced focal adhesion kinase (FAK)-associated adherens junction (AJ) assembly at cell-cell contacts coincident with formation of a prominent cortical actin ring. FTY720 also induced transmonolayer electrical resistance (TER) augmentation in HMVEC monolayers in both normoglycemic and hyperglycemic conditions, implying endothelial barrier enhancement. Similar to S1P, site-specific FAK tyrosine phosphorylation analysis revealed FTY720-induced FAK [Y576] phosphorylation without phosphorylation of FAK [Y397/Y 925]. Furthermore, FTY720 conditioned the phosphorylation profile of FAK [Y397/Y576/Y925] in hyperglycemic medium to the same pattern observed in normoglycemic medium. FTY720 challenge resulted in small GTPase Rac activation under hyperglycemic conditions, whereas increased Rho activity in hyperglycemic medium was restored to the basal level. Rac protein depletion by small interfering RNA (siRNA) technique completely abolished FTY720-induced FAK [Y576] phosphorylation. These findings strongly suggest the barrier protective effect of FTY720 on HMVEC monolayers in hyperglycemic medium via S1P signaling, further implying the possibility of FTY720 as a therapeutic agent of diabetic vascular disorder.

KW - Cytoskeleton

KW - Diabetes mellitus

KW - Endothelial barrier function

KW - Human microvascular endothelial cell

KW - Transmonolayer electrical resistance

UR - http://www.scopus.com/inward/record.url?scp=70349902746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349902746&partnerID=8YFLogxK

U2 - 10.1152/ajpcell.00606.2008

DO - 10.1152/ajpcell.00606.2008

M3 - Article

C2 - 19657053

AN - SCOPUS:70349902746

VL - 297

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0002-9513

IS - 4

ER -